Business Context and Reporting Period
This Form 8-K Current Report was filed by Protagonist Therapeutics, Inc. on December 11, 2020, regarding events occurring on December 10, 2020. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Newark, California. The report details the execution of an underwriting agreement for a public offering of common stock.
Key Financial Metrics
The filing discloses specific terms regarding a capital raise rather than operational financial performance metrics such as revenue or profit.
- Shares Offered: 4,761,904 shares of common stock.
- Public Offering Price: $21.00 per share.
- Price to Company: $19.74 per share (net of underwriting discounts).
- Expected Gross Proceeds: Approximately $100.0 million.
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 714,285 additional shares.
- Maximum Potential Proceeds: Approximately $115.0 million if the over-allotment option is exercised in full.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report.
Material Changes
The primary material change is the initiation of a public equity offering. The company entered into an underwriting agreement with J.P. Morgan Securities LLC, SVB Leerink LLC, and Piper Sandler & Co. This transaction represents a significant increase in the company's capital base pending the closing of the offering, which is expected on December 15, 2020.
Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The offering is being made pursuant to an effective registration statement on Form S-3ASR. The closing is subject to customary conditions.
Risks and Contingencies: The Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions. The agreement notes that representations were made solely for the benefit of the parties and may be subject to limitations or confidential disclosures exchanged between the parties.
Unusual Items: None reported beyond the standard terms of the underwriting agreement.
Investor Verification Checklist
- Verify the final closing date of the offering (expected December 15, 2020) and whether the over-allotment option was exercised.
- Confirm the actual net proceeds received after deducting underwriting discounts and offering expenses.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification clauses and termination rights.
- Check subsequent filings for the impact of this capital raise on the company's cash runway and dilution to existing shareholders.